SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending as traders discuss Trump's potential executive action to reclassify marijuana, sparking hope for the cannabis sector. The community is debating the implications of rescheduling, potential short squeezes, and comparing TLRY to other cannabis stocks. Some are also expressing skepticism, citing past disappointments and the need for concrete action.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's stock is experiencing volatility despite strong earnings, with analysts' target prices driving much of the current discussion. While the company beat expectations and offered positive guidance, some investors are taking profits, and others are concerned about future growth potential in non-AI sectors. The community is debating the sustainability of Broadcom's valuation and the impact of AI revenue projections.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its roots in cannabis culture and its presence on the Solana blockchain. Many are drawn to its positioning as a 'culture coin' with a focus on creativity and community building. Comparisons to Bitcoin are frequent, with the community emphasizing a vision of going 'way higher'.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors anticipate its Autonomy and AI Day, where the company is expected to reveal advancements in its self-driving technology and AI capabilities, with community chatter focusing on potential partnerships and the impact on competition with Tesla. Discussions also include analyst target price updates and debate over Rivian's valuation as a tech versus automotive company, alongside concerns about cash flow and production costs.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending after a Q3 earnings beat, raised full-year guidance, a CEO succession plan, and a buyback authorization, leading to analyst target price revisions. The community is discussing the potential for analyst upgrades and whether the stock can hold its gains amidst a challenging year. Some traders are pointing to strong execution, long-term visibility, and growth in China as reasons for renewed confidence.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is gaining significant traction, fueled by community enthusiasm and its association with the Ethereum ecosystem. Discussions highlight its potential as a leading meme token and a beneficiary of renewed interest in ETH, with some even suggesting it could be the next PEPE. The community emphasizes strong fundamentals, a compelling narrative, and increasing accumulation from experienced traders.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as the aerospace sector gains momentum, potentially fueled by speculation around a SpaceX IPO and renewed interest in space infrastructure. The community is discussing the company's growth potential, upcoming launches, and Neutron rocket development, with some analysts projecting significant upside. Positive sentiment is also emerging related to AI data centers in space, potentially creating further opportunities for Rocket Lab.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

GLSI is trending due to anticipation surrounding an upcoming presentation and speculation about potential news, possibly at the SABCS conference. Community members are focused on the high short borrow rate and the possibility of a short squeeze, with some expressing FOMO and discussing technical indicators. The overall sentiment suggests a belief in the company's long-term potential, particularly regarding its breast cancer treatment.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to significant intraday volatility, with community members actively discussing a potential short squeeze and the impact of a recent conference. The stock's price swings are also influenced by its low float and sector momentum, particularly related to Bitcoin's movements. Some traders are wary of a potential offering and the company's compliance with listing requirements.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending as the community discusses recent investments in Ukrainian drone technology and potential benefits from increased defense spending. Bullish sentiment is fueled by the company's growing presence in the drone and counter-drone space, with speculation around upcoming announcements and price target increases. Traders are actively monitoring key price levels for breakout opportunities, and whether it could trigger a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium...

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's...

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast...

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR...

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of...

<ul class="summary-bullets"><li>In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75%.</li><li>In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted.</li><li>CEO Lewis H. Bender said that the company has initiated randomized controlled studies, including a late-stage study in sarcoma. &nbsp;</li></ul>Shares of Intensity Therapeutics, Inc. (INTS) jumped 282% on Thursday morning after the company announced the publication of positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers.In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75% and a median overall survival of 11.9 months in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.intensitytherapeutics.com/news-events/press-releases/detail/112/intensity-therapeutics-inc-announces-publication-of">said</a>.In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted. In a clinical trial, measuring the median overall survival is one way to assess the effectiveness of a new treatment.INT230-6 induced a qualitative decrease in proliferating cancer cells in injected tumors, and pharmacokinetic results showed that greater than 95% of the active cytotoxic agents remained in the injected tumors, Intensity Therapeutics said.Furthermore, 15 of 64 patients in the trial survived for more than 21 months, the company noted.<h2 class="st-heading-2">What Did Company Executives Say?</h2>“Given the drug's mechanism of action and the data reported in this paper from over 20 types of metastatic solid cancers, such as breast, sarcoma, pancreatic, lung, and head and neck, we believe the study results show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy.” Lewis H. Bender, CEO, Intensity TherapeuticsThe CEO added that the company has initiated randomized controlled studies, including a late-stage study in sarcoma. This rare cancer originates in the body's connective tissues, such as bone, muscle, fat, and cartilage.INT30-6 consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule. In addition to local disease control and direct tumor killing, it causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INTS">INTS stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.INTS stock is down 42% this year and approximately 67% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sensei-biotherapeutics-halts-lead-drug-development-explores-sale-or-merger-options/cLGFvQbR3xf">Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Retail Going Gaga Over INTS Stocks Today?

The firm announced positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers, with 15 of 64 patients in the trial surviving for more than 21 months.

Equity

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal Intensity...

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Intensity Therapeutics Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

INTS
INTENSITY THERAPEUTICS, INC.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INTS News

INTSINTENSITY THERAPEUTICS, INC.